The European Commission, the European Union's Chief Medicines Regulators (CMPs) and the European Medicines Agency (EMA) have published the 2022-2016 work programme of the Accelerating Clinical Trials in the EU (ACT EU) initiative.
ACT EU, launched in January 2022, seeks to transform the way clinical trials are initiated, designed and conducted. The aim is to further develop the European Union (EU) as a hub for clinical research, promote the development of high-quality, safe and effective medicines and better integrate clinical research into the European health system. ACT EU will strengthen the European environment for clinical trials, while maintaining the high level of protection of trial participants, data robustness and transparency that EU citizens expect.
The ACT EU multi-annual work programme builds on the Clinical Trials Regulation (CTR), which entered into force in January 2022, and the activities of the European regulatory network to support clinical trials. The work plan focuses on key areas such as innovation in clinical trials, robust methodologies and collaboration between stakeholders.
The ACT EU work plan is structured according to the ten priority actions for ACT EU and has been developed based on the strategy recommendations of the European Medicines Authorities Network. For 2023, these include:
- Large, multinational clinical trials: Establish a support process specifically targeted at academic sponsors to make the EU a more attractive territory for conducting clinical research.
- Implementation of the CTR: Special focus on the Clinical Trials Information System (CTIS) and on training activities for the CTR and on solving any problems encountered by clinical trial sponsors.
- Platform for multiple stakeholders: To be created in 2023 to facilitate the evolution of the clinical trial environment through regular dialogue between all stakeholders, including patients, healthcare professionals and academics, to find practical solutions to enable and drive change.
- Modernising good clinical practice: ACT EU will support not only the adoption but also the implementation of revised EU guidelines in the field of technology and clinical trial design.
Facilitate innovative clinical trial methods: The initiative will issue guidance on decentralised clinical trials by the end of 2022 and publish a methodology roadmap to identify and prioritise key developments in clinical trial methods.
(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source